No Data
Asieris Signs Supply Deal With US CDC for Free-Living Amoeba Infection Treatment
Express News | Asieris and Cdc Sign Investigational Product Supply Agreement for Apl-1202 in Free-Living Amoeba Infections Treatment Under Expanded Access Investigational New Drug Program
Yahong Medical (688176.SH) approximately 6.8005 million restricted shares will be listed and circulated starting from January 7.
Yahong Pharmaceutical (688176.SH) announced that the restricted shares for this listing circulation are from the company's initial public offering prior to...
Asia Rainbow Pharmaceuticals (688176.SH): Shareholder voluntarily commits to extend the lock-up period of shares.
Glory Holdings reported on December 27 that Yahon Pharmaceutical (688176.SH) announced that it recently received a commitment letter from the company's Shareholders regarding the voluntary extension of the lock-up period for restricted shares. Based on confidence in the company's future development prospects and recognition of its investment value, the company's controlling Shareholder and actual controller Mr. PANKE's concerted actors, Pan-Scientific Holdings Co., Ltd., Taizhou Donghong Enterprise Management Center (Limited Partnership), and Taizhou Yahon Enterprise Management Center (Limited Partnership), a total of three Shareholders, committed to lock up all the shares they Hold prior to the company's initial public offering.
Jiangsu Yahong Meditech Co., Ltd.'s (SHSE:688176) Intrinsic Value Is Potentially 88% Above Its Share Price
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Report for the Third Quarter of 2024
No Data
